| 1 | 10061 | LAO-PA015 | ETCTN | Solid Tumor | Active | A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors | I | 24/36 | N/A | INTERVENTION |
| 2 | 10301 | LAO-CT018 | ETCTN | Male Reproductive System Cancer | Active | A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | I/II | 9/24 | N/A | INTERVENTION |
| 3 | 10330 | LAO-CT018 | ETCTN | Bone Cancer | Temporarily Closed to Accrual | A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | II | 19/32 | N/A | INTERVENTION |
| 4 | 10387 | EDDO-NY313 | ETCTN | AIDS-related Malignancy and Condition;Solid Tumor | Active | Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection | I | 3/18 | N/A | INTERVENTION |
| 5 | 10406 | LAO-PA015 | ETCTN | Gastrointestinal Cancer | Active | Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers | I | 6/90 | N/A | INTERVENTION |
| 6 | 10504 | LAO-NCI | ETCTN | Soft Tissue Cancer/Sarcoma | Active | A Randomized Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | II | 1/77 | N/A | INTERVENTION |
| 7 | 10507 | LAO-MA036 | ETCTN | Miscellaneous and Metastatic Cancer | Active | A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma | I/II | 3/18 | N/A | INTERVENTION |
| 8 | 10508 | EDDO-10508 | ETCTN | Lymphoma | Active | A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | I | 0/27 | N/A | INTERVENTION |
| 9 | 9892 | LAO-PA015 | ETCTN | AIDS-related Malignancy and Condition;Female Reproductive System Cancer | Active | Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer | I | 12/76 | N/A | INTERVENTION |
| 10 | 9938 | LAO-PA015 | ETCTN | Solid Tumor | Active | Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors | I | 65/66 | N/A | INTERVENTION |
| 11 | A021806 | ALLIANCE | NCTN | Gastrointestinal Cancer | Active | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | III | 129/352 | N/A | INTERVENTION |
| 12 | A021901 | ALLIANCE | NCTN | Endocrine Cancer | Active | Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors | II | 0/108 | N/A | INTERVENTION |
| 13 | A041703 | ALLIANCE | NCTN | Leukemia | Active | A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease | II | 52/64 | N/A | INTERVENTION |
| 14 | A051902 | ALLIANCE | NCTN | Lymphoma | Active | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | II | 10/182 | N/A | INTERVENTION |
| 15 | A071401 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Active | Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations | II | 84/124 | 416 | SCREENING, INTERVENTION |
| 16 | A091903 | ALLIANCE | NCTN | Skin Cancer | Active | A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma | II | 1/99 | N/A | INTERVENTION |
| 17 | A171901 | ALLIANCE | NCORP | Lung, Mediastinal, and Pleural Cancer | Active | Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice) | II | 81/100 | N/A | INTERVENTION |
| 18 | A211801 | ALLIANCE | NCORP | N/A | Active | BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation | III | 0/300 | N/A | INTERVENTION |
| 19 | A212102 | ALLIANCE | NCORP | Miscellaneous and Metastatic Cancer | Active | Blinded Reference Set For Multicancer Early Detection Blood Tests | Other | N/A | N/A | OTHER |
| 20 | AMC-112 | AMC | MISCELLANEOUS | AIDS-related Malignancy and Condition | Temporarily Closed to Accrual | Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma | I | 0/20 | 0 | SCREENING, INTERVENTION |
| 21 | DCP-001 | DCP | NCORP | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) | Other | N/A | N/A | OTHER |
| 22 | EA1181 | ECOG-ACRIN | NCTN | Breast Cancer | Active | EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer) | II | 1594/2156 | N/A | INTERVENTION |
| 23 | EA2192 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | II | 25/152 | N/A | INTERVENTION |
| 24 | EA5163 | ECOG-ACRIN | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis | III | 455/846 | N/A | INTERVENTION |
| 25 | EA6141 | ECOG-ACRIN | NCTN | Skin Cancer | Active | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | II/III | 359/600 | N/A | INTERVENTION |
| 26 | EA8134 | ECOG-ACRIN | NCTN | Male Reproductive System Cancer | Active | InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | III | 62/200 | N/A | INTERVENTION |
| 27 | EAA173 | ECOG-ACRIN | NCTN | Myeloma | Active | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | III | 117/288 | N/A | INTERVENTION |
| 28 | NRG-BR005 | NRG | NCTN | Breast Cancer | Temporarily Closed to Accrual | A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery | II | 105/175 | N/A | INTERVENTION |
| 29 | NRG-GU012 | NRG | NCTN | Kidney Cancer | Active | Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) | II | 0/240 | N/A | INTERVENTION |
| 30 | NRG-GY022 | NRG | NCTN | Solid Tumor | Active | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | I | 220/250 | N/A | INTERVENTION |
| 31 | PBTC-051 | PBTC | MISCELLANEOUS | CNS Cancer (Primary tumor) | Active | Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma | I | 31/45 | N/A | INTERVENTION |
| 32 | PEPN2111 | PEP-CTN | MISCELLANEOUS | Bone Cancer;CNS Cancer (Primary tumor);Lymphoma;Solid Tumor | Temporarily Closed to Accrual | A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients with Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma | I/II | 9/38 | N/A | INTERVENTION |
| 33 | S0820 | SWOG | NCORP | Gastrointestinal Cancer | Active | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | III | 342/389 | N/A | INTERVENTION |
| 34 | S1501 | SWOG | NCORP | Breast Cancer | Active | Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III | III | 284/817 | 303 | SCREENING, INTERVENTION |
| 35 | S1712 | SWOG | NCTN | Leukemia | Active | A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease | II | 78/84 | N/A | INTERVENTION |
| 36 | S1914 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC | III | 134/480 | N/A | INTERVENTION |
| 37 | S1933 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | II | 25/47 | N/A | INTERVENTION |
| 38 | S1937 | SWOG | NCTN | Urothelial/ Bladder Cancer | Active | A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy | III | 14/465 | N/A | INTERVENTION |
| 39 | S2005 | SWOG | NCTN | Lymphoma | Temporarily Closed to Accrual | A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) | II | 1/62 | N/A | INTERVENTION |
| 40 | S2012 | SWOG | NCTN | Endocrine Cancer | Active | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | II/III | 2/189 | N/A | INTERVENTION |
| 41 | S2013 | SWOG | NCORP | N/A | Active | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Other | N/A | N/A | OTHER |
| 42 | 10076 | LAO-TX035 | ETCTN | Myeloma | Active | A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma | I | 28/40 | N/A | INTERVENTION |
| 43 | 10184 | LAO-NCI | ETCTN | Head and Neck Cancer | Active | Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | I | 5/34 | N/A | INTERVENTION |
| 44 | 10208 | LAO-11030 | ETCTN | Gastrointestinal Cancer | Active | A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma | I/II | 37/74 | 440 | SCREENING, INTERVENTION |
| 45 | 10214 | LAO-MD017 | ETCTN | Gastrointestinal Cancer;Skin Cancer;Solid Tumor | Temporarily Closed to Accrual | Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers | I | 12/16 | N/A | INTERVENTION |
| 46 | 10272 | NCICCR | MISCELLANEOUS | Male Reproductive System Cancer | Active | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | II | 202/200 | N/A | INTERVENTION |
| 47 | 10327 | LAO-CA043 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Temporarily Closed to Accrual | A Phase I Trial of MLN0128 (Sapanisertib) and Telaglenastat (CB-839) HCL in Advanced NSCLC Patients | I | 13/85 | N/A | INTERVENTION |
| 48 | 10335 | LAO-CT018 | ETCTN | Leukemia;Lymphoma | Active | A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) | I | 4/30 | N/A | INTERVENTION |
| 49 | 10389 | LAO-OH007 | ETCTN | Gastrointestinal Cancer | Temporarily Closed to Accrual | A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) with Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer | I | 4/33 | N/A | INTERVENTION |
| 50 | 10422 | LAO-CT018 | ETCTN | Female Reproductive System Cancer | Temporarily Closed to Accrual | A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer | I | 5/42 | N/A | INTERVENTION |